Pharmaceutical company AbbVie (NYSE: ABBV) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.8% year on year to $13.98 billion. Its non-GAAP profit of $2.65 per share was 0.7% below analysts’ consensus estimates.
Is now the time to buy ABBV? Find out in our full research report (it’s free for active Edge members).
AbbVie (ABBV) Q1 CY2026 Highlights:
- Revenue: $13.98 billion vs analyst estimates of $14.75 billion (4.8% year-on-year growth, 5.2% miss)
- Adjusted EPS: $2.65 vs analyst expectations of $2.67 (0.7% miss)
- Adjusted Operating Income: $6.13 billion vs analyst estimates of $6.14 billion (43.8% margin, in line)
- Management lowered its full-year Adjusted EPS guidance to $14.18 at the midpoint, a 2% decrease
- Operating Margin: 28.5%, in line with the same quarter last year
- Constant Currency Revenue rose 10.3% year on year, in line with the same quarter last year
- Market Capitalization: $360.6 billion
StockStory’s Take
AbbVie’s first quarter results for 2026 exceeded management’s guidance midpoint and internal expectations, with adjusted earnings per share and revenue coming in above what the company had projected for itself. Management attributed the quarter’s outperformance to robust growth in its immunology and neuroscience portfolios, particularly through the continued momentum of Skyrizi and Rinvoq in psoriatic disease and inflammatory bowel disease. CEO Robert Michael highlighted, “Momentum in immunology and neuroscience is delivering share gains in growing markets,” while commercial chief Jeff Stewart pointed to Skyrizi’s strong efficacy data in hard-to-treat areas like genital and scalp psoriasis as a competitive advantage. Neuroscience revenues also benefited from strong demand for migraine and psychiatric treatments.
Looking ahead, AbbVie’s updated guidance reflects both optimism and caution. Management expects continued growth from its immunology and neuroscience franchises, supported by new product launches and pipeline advancements, and has raised its full-year adjusted EPS outlook based on strong Q1 performance. CEO Robert Michael emphasized, “We are investing in the business at record levels, have financial flexibility to pursue compelling business development, and will continue to augment our portfolio through both internal R&D and strategic transactions.” While management remains confident in the long-term growth trajectory, they cited competitive dynamics and macroeconomic headwinds as ongoing challenges.
Key Insights from Management’s Remarks
Management credited the quarter’s performance to strong execution in core therapeutic areas and highlighted several strategic investments and pipeline developments that are expected to shape future growth.
- Immunology leadership: Skyrizi and Rinvoq delivered double-digit operational sales growth, with Skyrizi gaining significant share in both psoriatic disease and inflammatory bowel disease (IBD). Management cited clinical data supporting Skyrizi’s durable efficacy and expanded FDA-approved indications as key differentiators in a competitive market.
- Neuroscience portfolio momentum: The neuroscience franchise posted strong revenue gains, driven by leading migraine therapeutics and solid results in psychiatric and Parkinson’s disease treatments. The launch of new products, such as VYALEV and preparations for Tavapadon, is expected to further strengthen this segment.
- Oncology pipeline expansion: While oncology revenues declined 3% on an operational basis due to pressure on IMBRUVICA, growth in drugs like Venclexta and the closing of the Remagen deal for a novel PD-1 VEGF bispecific antibody signal continued investment in next-generation cancer therapies. Early-stage data and regulatory filings for new oncology assets were highlighted as future growth drivers.
- Strategic capital investments: AbbVie announced major investments in U.S. manufacturing infrastructure, including a $1.4 billion campus in North Carolina and new facilities in North Chicago, to support long-term innovation and supply chain reliability.
- Business development focus: Management reinforced its commitment to augmenting the pipeline through external innovation, with recent acquisitions and partnerships in immunology, neuroscience, and obesity, aiming to sustain portfolio growth and defend against competitive threats.
Drivers of Future Performance
AbbVie’s forward guidance is shaped by sustained growth in immunology and neuroscience, increased R&D investment, and a cautious approach to competitive dynamics and consumer demand.
- Product pipeline advancement: Management expects upcoming regulatory approvals and label expansions for key drugs such as Skyrizi and Rinvoq to drive top-line growth, especially as new indications in dermatology and gastroenterology come online. Additional launches in neuroscience and Parkinson’s disease are set to diversify revenue streams.
- Increased R&D and manufacturing investment: AbbVie is ramping up research and development spending and building new manufacturing capacity to support future innovation. This includes ongoing clinical trials for obesity, oncology, and immunology assets, which management believes will position the company for long-term growth, while maintaining a strong operating margin outlook.
- Competitive and macroeconomic headwinds: The company anticipates ongoing biosimilar competition, particularly for legacy products like HUMIRA, as well as inflationary pressures in the aesthetics segment and potential pricing erosion in immunology. Management noted that while these risks are factored into guidance, execution on new product launches and pipeline milestones will be critical to offsetting these challenges.
Catalysts in Upcoming Quarters
In the upcoming quarters, the StockStory team will be closely monitoring (1) regulatory approvals and new indication launches for Skyrizi, Rinvoq, and Tavapadon, (2) progress on R&D milestones in obesity and oncology, especially interim and pivotal trial readouts, and (3) the impact of manufacturing capacity expansions on supply reliability and margin trends. Execution on business development and integration of new assets will also be key performance indicators.
AbbVie currently trades at $203.43, up from $197.69 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
